Path-27. Identifying the Genetic Signature of Response in a Phase Ii Study of Tumor Treating Fields in Recurrent Glioblastoma

Neuro-Oncology - United Kingdom
doi 10.1093/neuonc/noy148.683
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Oxford University Press (OUP)

Related search

Tumor Treating Fields in Combination With Paclitaxel in Recurrent Ovarian Carcinoma: Results of the INNOVATE Pilot Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2018English

PC3 - 179 Analysis of Glioblastoma Physical Characteristics in Patients Benefiting From Tumor Treating Electric Fields Therapy

Canadian Journal of Neurological Sciences
MedicineNeurology
2016English

Bevacizumab and Fotemustine for Recurrent Glioblastoma: A Phase II Study of AINO (Italian Association of Neuro-Oncology)

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2013English

Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Effects of Tumor Treating Fields (TTFields) on Glioblastoma Cells Are Augmented by Mitotic Checkpoint Inhibition

Cell Death Discovery
Cancer ResearchMolecular NeuroscienceImmunologyCell BiologyCellular
2018English

Biological Activity of Tumor-Treating Fields in Preclinical Glioma Models

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2017English

Genetic Basis of Radiation Response in Glioblastoma Multiforme

Nature Genetics
Genetics
2001English

Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune® System

Clinical Medicine Insights: Oncology
Oncology
2019English

Response to Imatinib as a Function of Target Kinase Expression in Recurrent Glioblastoma

SpringerPlus
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy